Thus, our findings suggest that including ATM mutational status in lung cancer as a mechanistic biomarker for MEK inhibitors can improve patient stratification, potentially extending the applicability of these drugs beyond RAS and BRAF mutant tumours. The gene discussed is BRAF; the disease is neoplasm.